Peptides for Disease Research

We’re rapidly producing custom peptides and peptide libraries for the major proteins of SARS-COV-2. With high quality products available fast for researchers combating Covid19, come and see Mimotopes for all of your peptide needs.

Custom Peptide Libraries

The advantage of our proprietary parallel synthesis technology is that Mimotopes can synthesise hundreds of peptides simultaneously, and thus greatly reduce the price and time to delivery.

High quality Peptide Libraries affordable prices

30 Years Experience

Mimotopes is the founder of peptide library technology. We have only continued to grow and learn over the decades – now our expertise is unrivaled.

We work tirelessly to stay ahead of the game to ensure, as always, that we supply the best possible products, including SARS-CoV-2 peptides.

Efficient & Economical Screening Solutions

PepsetTM PeptideLibraries have dozens of potential applications. With applications in covid19 vaccine and drug development, disease screening, and epitope mapping, a peptide library can be exclusively designed to your specifications, for your research. 

  • Discover crucial residues with an Alanine Scan Library
  • Map epitopes with an Overlapping Library
  • Narrow down the shortest active sequences with a Truncated Library

Dozens of Options to Customise

A standard PepSetTM Peptide Library can be supplied as with a precise length and offset designed to best suit your assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence. Arrange a consultation to discuss your options and design your library.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Continuous manufacturing cautiously builds on hypeGo to article: In this issueGo to article: CSafe GlobalGo to article: ContentsGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: SHL Medical Company Insight Go to article: SHL MedicalGo to article: WR GraceGo to article: CommentGo to article: CMO agreements need to go public, but ‘glib’ onshoring not the answerGo to article: Biologic sales forecast to pass innovative small molecule sales in next five yeaGo to article: The telemedicine community has rallied to provide support to patients in UkraineGo to article: Osteoarthritis pipeline shifting from analgesics to disease-modifying treatmentsGo to article: BioLife SolutionsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: In DepthGo to article: Continuous manufacturing builds on hype but adoption remains gradual Go to article: Can Relmada’s fast-acting pill for major depressive disorder compete inGo to article: Access to CAR-T therapies in Central and Eastern Europe in “catch-up” mode compaGo to article: How ambitious are the emissions targets of pharma and biotech companies?Go to article: Should Covid-19 clinical trial plans still centre around EUAs?Go to article: BEA TechnologiesGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DataGo to article: Top and emerging locations for M&A deals in the pharma industryGo to article: Deals relating to genomics increased in the pharma industry in H2 2021Go to article: Pharma industry companies are increasingly innovating in machine learningGo to article: BaxterGo to article: EventsGo to article: Next issue